新药药理、肿瘤药理、精氨酸甲基化与肿瘤

承担的研究项目

        企事业单位委托科技项目5项，中央高校基本科研业务费专项资金面上项目2项，英国威廉希尔唯一官网本科教育教学项目1项。

近年的代表性论著

        1. Shihao Zhu, Xiang Han, Ruiying Yang, Yizhen Tian, Qingqing Zhang, Yongjie Wu, Shuhong Dong^* and Baolai Zhang^*. Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF/MS. Chem-Biol Interact, 2023, 370: 110305. (Q1, IF =5.1678).

        2. Ruiying Yang, Shuhong Dong, Jinghui Zhang, Shihao Zhu, Guoliang Miao, and Baolai Zhang^*. Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo. Mol Cell Biochem, 2023, 478: 1031-1044. (Q2, IF=4.2997).

        3. Qingqing Zhang, Ruiying Yang, Yizhen Tian, Suyin Ge, Xiaojuan Nan, Shihao Zhu Shuhong Dong and Baolai Zhang^*. Ribavirin inhibits cell proliferation, metastasis and prolongs survival in soft tissue Sarcomas by down-regulating both type I PRMT1 and Type II PRMT5. Basic Clin Pharmacol, 2022, 131(1):18-33. (Q2, IF =4.0837).

        4. Yizhen Tian, Weihu Yang, Ruiying Yang, Qingqing Zhang, Luyang Hao, Enze Bian, YuquanYang, Xuewei Huang, Yongjie Wu and Baolai Zhang^*. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol, 2022, 435:115829. (Q2, IF =4.460).

        5. Suyin Ge, Qingqing Zhang, Yonglin Chen, Yizhen Tian, Ruiying Yang, Xu Chen, Fang Li, and Baolai Zhang*. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol, 2021, 415:115450. (Q2, IF =4.460).

       6. Suyin Ge, Qingqing Zhang, Yizhen Tian, Luyang Hao, Jingru Duan, Baolai Zhang^*. Cell metabolic profiling of colorectal cancer via ¹H NMR. Clin Chim Acta, 2020, 510, 291-297. (Q1, IF =6.314).

        7. Baolai Zhang^*, Su Zhang, Lijuan Zhu, Xue Chen, Yunfeng Zhao, Li Chao, Juanping Zhou, Xing Wang, Xinyang Zhang, Nengqian Ma. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5. Toxicol Appl Pharmacol, 2017, 336:1-7. (Q2, IF=4.460).

        8. Baolai Zhang^*, Shuhong Dong, Zhongxin Li, Li Lu, Su Zhang, Xue Chen, Xiaobo Cen, and Yongjie Wu^*. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta‑catenin. J Transl Med, 2015, 13:394. (Q1, IF=8.440).

        9. 主编普通高等教育“十三五”规划教材/全国高等医药院校规划教材《药理学实验指导》，2020，清华大学出版社；参编普通高等教育“十一五”国家级规划教材《药理学教程》(第7版)，2021，高等教育出版社。